A ntimicrobial prophylaxis is a cornerstone of perioperative management of patients undergoing orthopedic procedures because of the devastating consequences of postoperative infection. Skin and soft tissue infection and osteomyelitis are costly complications of orthopedic surgery and result in hospital readmission, the need for additional surgical procedures including hardware removal, increased length of hospital stay, and additional costs for prolonged antimicrobial therapy.
A ntimicrobial prophylaxis is a cornerstone of perioperative management of patients undergoing orthopedic procedures because of the devastating consequences of postoperative infection. Skin and soft tissue infection and osteomyelitis are costly complications of orthopedic surgery and result in hospital readmission, the need for additional surgical procedures including hardware removal, increased length of hospital stay, and additional costs for prolonged antimicrobial therapy. 1 The use of evidence-based systemic antimicrobial prophylaxis for all orthopedic procedures is critical. 2 Evidence-based prophylaxis is emphasized because antimicrobial use in the perioperative period is not without risk. Orthopedic clinicians must consider the often overlooked risks of non-evidence-based antimicrobial prophylaxis, including antimicrobial resistance and Clostridium difficile infection.
From an institutional and health care system perspective, the choice of antimicrobial and the duration of prophylaxis have the potential to increase antimicrobial resistance and the proliferation of resistant organisms. Vancomycin is not recommended for routine use for prophylaxis, and should only be used when specific underlying factors are present. 2, 3 Institutions are encouraged to develop specific internal recommendations, but generally vancomycin should be used routinely during periods of a specific cluster of infection, including methicillin-resistant Staphylococcus aureus (MRSA) or Staphylococcus epidermidis.
Additionally, patients with known MRSA colonization should receive surgical prophylaxis with vancomycin. Patients with reported allergy to penicillin should also receive vancomycin. In clinical practice, the nature of reported allergy is an important consideration, and only patients with reported Type I (IgEmediated) reactions to penicillin or exfoliative dermatitis (Stevens-Johnson syndrome or toxic epidermal necrolysis) should receive vancomycin in lieu of a first-generation cephalosporin.
2 Type I-mediated reactions are characterized by anaphylaxis, urticaria, or bronchospasm. In the absence of these reported reactions, patients can safely receive a first-generation cephalosporin. To help identify patients who may still receive cephalosporin therapy, clarifying the nature of reported allergic reactions can help reduce vancomycin use.
As advocated by the Healthcare Infection Control Practices Advisory Committee, overuse of vancomycin can increase a patient's risk for vancomycin-resistant Enterococcus colonization and infection. 4 It may also increase the possibility of the emergence of vancomycin-intermediate or vancomycin-resistant S aureus or S epidermidis. Additionally, the prolonged use of perioperative prophylaxis with any agent can contribute to the development of multidrug-resistant organisms. This is especially true of third-generation cephalosporins such as ceftriaxone, ceftazidime, and cefotaxime, which can increase the rate of difficult to treat extended-spectrum beta-lactamase-producing organisms. 5 Therefore, in orthopedic practice, restricting the use of vancomycin to specific and limited patient populations will help reduce antimicrobial resistance.
Perioperative prophylaxis also increases a patient's risk of developing C difficile infection. Case reports indicate that infection is possible following a single dose of prophylaxis, but the agents n guest editorial used and the duration of antimicrobial prophylaxis are significant risk factors for the development of disease. 2 Cefazolin and other first-generation cephalosporins are preferred for antimicrobial prophylaxis and are as effective as second-and third-generation agents. The first-generation agents also confer a lower risk of C difficile. Although there has been controversy in the past, the best available evidence indicates that the use of prophylaxis beyond 24 hours postoperatively does not confer additional benefits in patients undergoing spine operations, hip fracture repair, or joint replacement. 2 Additionally, there is no evidence to support the use of antimicrobial prophylaxis until drains and catheters are removed. 2, 6 Limiting the use of antimicrobial prophylaxis to first-generation cephalosporins during the first 24 hours postoperatively can help minimize the risk of C difficile and prevent surgery-associated infection.
ConClusion
The risk of infection following orthopedic procedures is an important consideration driving the use of antimicrobial prophylaxis, and the use of antimicrobials perioperatively plays an important role in preventing infection. However, these agents cannot be considered completely benign. The risks and the benefits of prophylaxis must be weighed to help determine the optimal course of treatment for the patient. Agents for prophylaxis should be chosen to help minimize the development of resistant organisms and their duration should be limited to help minimize resistance and the risk of C difficile infection.
